Título em Hematologia e Hemoterapia common mistakes
Título em Hematologia e Hemoterapia · Understand the traps and how to avoid them.
Classifying a normocytic anemia with high reticulocytes as a production failure and ordering bone marrow studies before checking the reticulocyte index against the degree of anemia.
Candidates memorize 'low reticulocyte = hypoproliferative, high = hemolysis/blood loss' but forget to correct the reticulocyte percentage for the hematocrit, so a mildly elevated raw percentage in severe anemia is misread as adequate marrow response.
What to do instead
Always compute the corrected reticulocyte count (retic % × patient Hct / normal Hct) or the reticulocyte production index before interpreting marrow response; classify as hyperproliferative only when the corrected index exceeds 2–3, then proceed to hemolysis markers (LDH, haptoglobin, indirect bilirubin) or bleeding history.
Reading a peripheral smear and attributing microcytosis to iron deficiency without checking the mentzer index, iron studies, and hemoglobin electrophoresis ordering sequence, and missing coexisting thalassemia trait.
Iron deficiency is the most taught cause of microcytosis, and candidates anchor on it; the discrimination between iron deficiency and thalassemia trait requires pattern recognition (RDW, target cells, basophilic stippling) that is under-practiced.
What to do instead
For microcytic anemia, systematically compare RDW (high in iron deficiency, often normal in thalassemia trait), Mentzer index (MCV/RBC <13 favors thalassemia), ferritin with CRP interpretation, and hemoglobin electrophoresis; remember that iron deficiency can normalize thalassemia indices and both can coexist.
Diagnosing acute promyelocytic leukemia (APL) only after cytogenetics returns, delaying ATRA initiation while waiting for PML-RARA confirmation.
Candidates are trained to confirm diagnosis before treatment and fear starting ATRA without molecular proof; they also under-recognize the DIC-pattern coagulopathy that should trigger urgent suspicion.
What to do instead
Treat APL as a hematologic emergency: when promyelocytes with Auer rods, low fibrinogen, elevated D-dimer, and prolonged PT are present, start ATRA immediately on clinical/morphologic suspicion and confirm with PML-RARA (FISH or RT-PCR) in parallel; do not wait for karyotype.
Applying the same prognostic stratification to chronic lymphocytic leukemia and acute myeloid leukemia, mixing up which markers belong to which disease (e.g., using TP53 and IGHV status in AML or FLT3/NPM1 in CLL).
Prognostic panels are taught as lists without anchoring each marker to its disease context, and both diseases use cytogenetics and molecular testing, so markers blur together under exam pressure.
What to do instead
Build a disease-anchored table: CLL uses Rai/Binet staging, IGHV mutational status, del(17p)/TP53, del(11q), and beta-2 microglobulin; AML uses ELN risk groups with cytogenetics plus NPM1, FLT3-ITD, CEBPA, and TP53. Rehearse which marker changes therapy (e.g., FLT3 inhibitors, ibrutinib/venetoclax) rather than memorizing lists.
Transfusing packed red cells based on a single hemoglobin value without assessing clinical status, and defaulting to a restrictive threshold in patients with active myocardial ischemia or symptomatic anemia.
The restrictive 7 g/dL threshold is over-generalized from critical care trials; candidates forget the excluded populations and the principle that symptoms and ischemia drive decisions more than numbers.
What to do instead
State the threshold with its context: 7 g/dL for stable hospitalized adults, 8 g/dL for most perioperative and cardiovascular disease patients, and individualized/liberal transfusion for active ischemia or symptomatic anemia; always mention that a single unit is reassessed before ordering a second.
Ordering crossmatch-compatible units for a patient with a positive antibody screen without first identifying the antibody and providing antigen-negative units, or assuming the electronic crossmatch remains valid.
Candidates equate 'crossmatch compatible' with 'safe' and do not link a positive antibody screen to the need for phenotyping and antigen-negative selection; the electronic crossmatch is valid only when the antibody screen is negative.
What to do instead
For a positive antibody screen, perform antibody identification (panel cells, enzyme/antiglobulin phases), select units negative for the corresponding antigen, and use a full antiglobulin crossmatch; remember clinically significant antibodies (Rh, Kell, Duffy, Kidd, MNS, Diego) and that the electronic crossmatch is prohibited once an alloantibody is known.
Managing a suspected acute hemolytic transfusion reaction by stopping the transfusion but omitting the clerical check, returning the unit and tubing to the blood bank, and reporting to hemovigilance.
The clinical steps (stop, maintain IV access, resuscitate) are well memorized, but the regulatory and investigation steps are treated as paperwork and dropped under exam time pressure.
What to do instead
Recite the full bundle in order: stop the transfusion, keep the line with saline, assess ABCs, verify patient and unit identity at the bedside, send the unit with tubing, post-transfusion samples (plasma free hemoglobin, DAT, repeat type and screen), and notify the blood bank and hemovigilance system; distinguish acute hemolytic, febrile non-hemolytic, allergic, TRALI, and TACO by timing and findings.
Clearing a platelet count of 50,000/µL for a neuraxial procedure or major surgery without distinguishing the thresholds for different procedures and without checking platelet function or antiplatelet drugs.
A single 'safe platelet number' is memorized and applied to all invasive procedures, ignoring that neuraxial anesthesia, neurosurgery, and minor procedures have different thresholds and that qualitative defects matter even with normal counts.
What to do instead
Attach a threshold to each procedure: generally >50,000/µL for major surgery and neuraxial anesthesia, >100,000/µL for neurosurgery or ophthalmic posterior segment surgery, >20,000/µL for prophylaxis in stable patients, and consider platelet function testing or drug washout when counts are normal but bleeding risk is qualitative.
Confusing graft-versus-host disease prophylaxis with graft-versus-host disease treatment, or mixing up which immunosuppressive regimen belongs to matched related versus haploidentical transplantation.
The prophylaxis and treatment drug lists overlap (calcineurin inhibitors, methotrexate, mycophenolate, antithymocyte globulin, post-transplant cyclophosphamide), and candidates memorize drug names without attaching them to the transplant platform and timing.
What to do instead
Map each regimen to its context: matched related/unrelated transplants typically use a calcineurin inhibitor plus methotrexate or mycophenolate; haploidentical transplants commonly use post-transplant cyclophosphamide-based platforms; treatment of established GVHD uses high-dose corticosteroids first-line with agents such as ruxolitinib or extracorporeal photopheresis for steroid-refractory disease.
Assessing apheresis indications by disease name alone without applying the ASFA category and the urgency of the clinical scenario, and confusing donor apheresis with therapeutic apheresis.
Candidates memorize a list of diseases treated by plasmapheresis but not the category system (first-line, second-line, adjunct) or the difference between therapeutic plasma exchange, cytapheresis, and peripheral blood stem cell collection.
What to do instead
For each apheresis question, state the modality (plasma exchange, red cell exchange, leukocytapheresis, photopheresis, stem cell collection), the ASFA category, and whether it is first-line or rescue; anchor classic examples such as plasma exchange for TTP, red cell exchange for severe sickle cell crisis or stroke, and stem cell collection after G-CSF mobilization for autologous transplant.